Jeff Prewett serves as the Regional Director for Hospital and Integrated Delivery Network (IDN) Accounts at Eli Lilly and Company, where he plays a pivotal role in shaping the company’s strategic approach across 28 states in the western United States. With a robust background in...
Jeff Prewett serves as the Regional Director for Hospital and Integrated Delivery Network (IDN) Accounts at Eli Lilly and Company, where he plays a pivotal role in shaping the company’s strategic approach across 28 states in the western United States. With a robust background in Managed Markets and Sales Leadership, Jeff has consistently delivered impressive results, particularly in the realm of B2B contracting and strategic development. His expertise in pharmaceutical sales and managed care has been instrumental in transforming the West Region from a position of customer equity weakness to one of strength, significantly enhancing employee engagement and fostering a culture of collaboration among field sales and account teams.
In his current role, Jeff is responsible for overseeing the Lilly USA Hospital/IDN Account Executive Team, focusing on building sustainable customer relationships and creating contractual agreements that drive business outcomes. His leadership has been critical in executing payer strategies and brand operations for a $3 billion small molecule portfolio, where he has led successful launch efforts that align with the company’s broader objectives in diabetes and biotechnology. Jeff’s strategic planning capabilities, combined with his deep understanding of healthcare dynamics, enable him to navigate complex market landscapes effectively.
Moreover, Jeff’s commitment to cross-functional team leadership has allowed him to cultivate strong partnerships across various departments, ensuring that marketing strategies are not only innovative but also aligned with the needs of healthcare providers and patients. His ability to synthesize insights from global marketing initiatives into actionable strategies at the regional level has positioned him as a key driver of Eli Lilly’s success in the competitive pharmaceutical landscape.
